检索
AI 对话
AI 辅写
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Pharmacokinetic (PK) Results From a Phase 3 Trial to Evaluate Pegunigalsidase Alfa Every 4 Weeks (Q4W) in Patients (Pts) With Fabry Disease Previously Treated With Agalsidase Beta or Agalsidase Alfa

Camilla Tøndel,Eric L. Wallace,Rossana Rocco,Einat Almon,Sari Alon, Liora Blinder-Haddad,Raul Chertkoff,David G. Warnock,Stephen Waldek,Antonio Pisani

Journal of the American Society of Nephrology（2022）

引用 0|浏览0
暂无评分
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要